Clinical Trial Detail

NCT ID NCT03202316
Title Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

inflammatory breast carcinoma


Atezolizumab + Cobimetinib + Eribulin

Age Groups: adult senior

No variant requirements are available.